iRadimed (NASDAQ:IRMD – Get Free Report) and PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.
Insider & Institutional Ownership
92.3% of iRadimed shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 34.6% of iRadimed shares are held by insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares iRadimed and PROCEPT BioRobotics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iRadimed | $86.34 million | 13.30 | $22.48 million | $1.79 | 50.18 |
| PROCEPT BioRobotics | $308.05 million | 3.26 | -$95.57 million | ($1.94) | -9.03 |
iRadimed has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for iRadimed and PROCEPT BioRobotics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iRadimed | 0 | 3 | 2 | 1 | 2.67 |
| PROCEPT BioRobotics | 2 | 9 | 3 | 2 | 2.31 |
iRadimed presently has a consensus target price of $120.00, suggesting a potential upside of 33.59%. PROCEPT BioRobotics has a consensus target price of $25.50, suggesting a potential upside of 45.63%. Given PROCEPT BioRobotics’ higher possible upside, analysts clearly believe PROCEPT BioRobotics is more favorable than iRadimed.
Volatility & Risk
iRadimed has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
Profitability
This table compares iRadimed and PROCEPT BioRobotics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iRadimed | 26.70% | 23.45% | 20.36% |
| PROCEPT BioRobotics | -32.53% | -30.62% | -22.10% |
Summary
iRadimed beats PROCEPT BioRobotics on 10 of the 15 factors compared between the two stocks.
About iRadimed
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
About PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
